BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8080453)

  • 1. Correlation of total and interstrand DNA adducts in tumor and kidney with antitumor efficacies and differential nephrotoxicities of cis-ammine/cyclohexylamine-dichloroplatinum(II) and cisplatin.
    Yoshida M; Khokhar AR; Kido Y; Ali-Osman F; Siddik ZH
    Biochem Pharmacol; 1994 Aug; 48(4):793-9. PubMed ID: 8080453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics of tissue disposition of cis-ammine/cyclohexylamine-dichloroplatinum(II) and cisplatin in mice bearing FSaIIC tumors.
    Yoshida M; Khokhar AR; Zhang YP; Thai G; Siddik ZH
    Cancer Chemother Pharmacol; 1994; 35(1):38-44. PubMed ID: 7987975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
    Kelland LR; Mistry P; Abel G; Loh SY; O'Neill CF; Murrer BA; Harrap KR
    Cancer Res; 1992 Jul; 52(14):3857-64. PubMed ID: 1617660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.
    McKeage MJ; Abel G; Kelland LR; Harrap KR
    Br J Cancer; 1994 Jan; 69(1):1-7. PubMed ID: 8286188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
    Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
    Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA-protein cross-linking by trans-[PtCl(2)(E-iminoether)(2)]. A concept for activation of the trans geometry in platinum antitumor complexes.
    Novakova O; Kasparkova J; Malina J; Natile G; Brabec V
    Nucleic Acids Res; 2003 Nov; 31(22):6450-60. PubMed ID: 14602903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different features of the DNA binding mode of antitumor cis-amminedichlorido(cyclohexylamine)platinum(II) (JM118) and cisplatin in vitro.
    Kostrhunova H; Vrana O; Suchankova T; Gibson D; Kasparkova J; Brabec V
    Chem Res Toxicol; 2010 Nov; 23(11):1833-42. PubMed ID: 20939593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines.
    Mellish KJ; Barnard CF; Murrer BA; Kelland LR
    Int J Cancer; 1995 Sep; 62(6):717-23. PubMed ID: 7558420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circumvention of platinum resistance: structure-activity relationship for homologous series of ammine/amine platinum(II) complexes in L1210 cell lines.
    Yoshida M; Khokhar AR; Siddik ZH
    Anticancer Drug Des; 1994 Oct; 9(5):425-34. PubMed ID: 7945726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.
    Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V
    Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
    Mellish KJ; Kelland LR; Harrap KR
    Br J Cancer; 1993 Aug; 68(2):240-50. PubMed ID: 8347478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of DNA adduct structure and distribution on the mutagenicity and genotoxicity of two platinum anticancer drugs.
    Yarema KJ; Wilson JM; Lippard SJ; Essigmann JM
    J Mol Biol; 1994 Mar; 236(4):1034-48. PubMed ID: 8120885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unique properties of DNA interstrand cross-links of antitumor oxaliplatin and the effect of chirality of the carrier ligand.
    Kasparkova J; Vojtiskova M; Natile G; Brabec V
    Chemistry; 2008; 14(4):1330-41. PubMed ID: 18022972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2.4-A crystal structure of the asymmetric platinum complex [Pt(ammine)(cyclohexylamine)]2+ bound to a dodecamer DNA duplex.
    Silverman AP; Bu W; Cohen SM; Lippard SJ
    J Biol Chem; 2002 Dec; 277(51):49743-9. PubMed ID: 12377787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tetravalent platinum complexes with ammine/amine carrier ligand configuration: circumvention of platinum resistance in vivo.
    Siddik ZH; Thai G; Yoshida M; Zhang YP; Khokhar AR
    Anticancer Drug Des; 1994 Dec; 9(6):495-509. PubMed ID: 7880375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic analysis of platinum after combined treatment of cisplatin and procainamide hydrochloride in mice bearing P388 leukemia.
    Vannozzi MO; Ottone M; Mariggiò MA; Cafaggi S; Parodi B; Cilli M; Lindup E; Viale M
    Anticancer Res; 2003; 23(2B):1509-16. PubMed ID: 12820417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY; Rogers PM; Kelland LR
    Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Instability of the monofunctional adducts in cis-[Pt(NH3)2(N7-N-methyl-2-diazapyrenium)Cl](2+)-modified DNA: rates of cross-linking reactions in cis-platinum-modified DNA.
    Payet D; Gaucheron F; Sip M; Leng M
    Nucleic Acids Res; 1993 Dec; 21(25):5846-51. PubMed ID: 8290343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative toxicity and renal distribution of the platinum analogs tetraplatin, CHIP, and cisplatin at equimolar doses in the Fischer 344 rat.
    Smith JH; Smith MA; Litterst CL; Copley MP; Uozumi J; Boyd MR
    Fundam Appl Toxicol; 1988 Jan; 10(1):45-61. PubMed ID: 3350229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.